Copyright
©The Author(s) 2022.
World J Gastroenterol. Dec 21, 2022; 28(47): 6743-6751
Published online Dec 21, 2022. doi: 10.3748/wjg.v28.i47.6743
Published online Dec 21, 2022. doi: 10.3748/wjg.v28.i47.6743
Figure 1 Number of therapeutic trials described in studies including 2 or more inflammatory bowel disease patients.
TNFi: Tumor necrosis factor inhibitor; TOF: Tofacitinib; UST: Ustekinumab; VDZ: Vedolizumab.
- Citation: Balderramo D. Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease. World J Gastroenterol 2022; 28(47): 6743-6751
- URL: https://www.wjgnet.com/1007-9327/full/v28/i47/6743.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i47.6743